Gapping up
In reaction to strong earnings/guidance:
- CPSI +11.2%, PERI +7.2%, SHOP +5.8%, TAP +5.6%, TEVA +3.5%, AKAM +3.4%, BG +3.4%, CNO +3.1%, BXMT +2.9%, CVS +2.8%, ACCO +2.5%, CVE +2%, ACGL +1.6%, AB +1.4%, ECOM +1.4%, LSCC +1.3%, AMCR +1.3%, PRI +1.2%, AMX +1.2%, NBL +1.2%, PEAK +1.1%, GOLD +0.8%, TW +0.7%
M&A news:
- CSGP +1.8% (acquires RentPath from Chapter 11 Bankruptcy for $588 mln in cash)
Other news:
- ADMS +8.7% (publishes final results from Parkinson's study that showed improvement)
- PRVL +4.9% (granted FDA Orphan Drug Designation for PR001 for the treatment of patients with Gaucher disease)
- ADVM +3.9% (prices 9.5 mln shares of common stock at $13.75 per share)
- MGI +3.6% (announces launch of MoneyGram FastSend)
- FGEN +2.4% (FDA accepts NDA for roxadustat for the treatment of anemia)
Analyst comments:
- SSL +5.3% (upgraded to Buy from Hold at HSBC Securities)
- ARDX +4.8% (initiated with a Buy at Citigroup)
- WYNN +3.6% (upgraded to Buy from Neutral at BofA/Merrill)
- WETF +2.9% (upgraded to Overweight from Equal-Weight at Morgan Stanley)
- MU +2.7% (upgraded to Buy from Neutral at UBS)
- LVS +2.4% (upgraded to Buy from Neutral at BofA/Merrill)
- QCOM +1.6% (upgraded to Outperform from Neutral at Daiwa Securities)
- NVDA +1% (target raised to Street-high $310 from $285 at Susquehanna)